Role of bioactive molecules and maternal immune cells in breast milk in type 2 diabetes mellitus risk reduction

Tajudeen Olanrewaju Yahaya and Mutiu Oyekunle Sifau

Abstract

Inadequate breastfeeding or its total neglect has been mentioned in several studies as a contributing factor to the globally rising incidence of Type 2 diabetes mellitus (T2DM). However, the anti-diabetic role of breast milk has not been given much attention. As such, this study was initiated to review and bring to update on the role of breastfeeding in the risk reduction of T2DM. Relevant information on the topic was retrieved from the reliable science databases, including PubMed, MedLine, Google Scholar, Researchgate, etc. The results showed that breast milk is not energy dense and contains several health-enhancing bioactive molecules, including adipokines, antimicrobial and growth factors, cytokines, nutrients, and immune cells. Adipokines interact with the central nervous system to modulate certain physiological processes involved in energy balance, thereby programming an infant to be at a reduced risk for overweight, obesity and T2DM later in life. The antimicrobial and growth factors, as well as immune cells and bioactive nutrients may stimulate the growth of beneficial bacteria and/or inhibit the growth of pathogens. Thus, strengthen neonate defense mechanisms to effectively prevent infections as well as short and long-term disorders such as obesity and T2DM. In conclusion, nursing mothers are advised to breastfeed babies adequately before introducing them to complementary foods. To cater to the need of babies who may not have access to breastfeeding, healthcare providers should formulate infant formula using breast milk components as basic constituents.

Introduction

Type 2 diabetes mellitus (T2DM) is a chronic and degenerative condition that disrupts blood glucose homeostasis. The disease begins either when the pancreatic β-cells produce too little insulin to maintain normal blood glucose ranges, or when the body fails to respond to the insulin produced. The immediate effect of T2DM is the high blood glucose level which, if allowed to persist for a long time, may lead to some complications involving multi-organ damage.1,2 The complications could be micro-vascular occurring in small blood vessels, e.g., retinopathy causing blindness, nephropathy resulting in kidney failure, and neuropathy leading to erectile dysfunction.3-5 It could also be macro-vascular occurring in large blood vessels, e.g., cardiovascular disorders (such as heart-attacks and strokes), and severe foot ulcer resulting in amputation.6-8

Due to its chronicity and complexity, DM exerts a huge socio-economic burden on the affected and the public, which collectively result in poor quality of life.5,6 DM is currently considered a global health threat consequence of its high morbidity and mortality rates, as well as huge budget, gulped yearly.2 An estimated sum of $727 billion was spent on all types of DM in 2017 and the figure could reach about $776 billion in the next few decades.6,7 The costs accrued to T2DM management alone were projected to increase from 200% in 2012 to 600% in 2050.11 In terms of mortality, about 4 million deaths worldwide were attributed to DM in 2017 and over 21 million newborns (1 in 7 births) were affected by DM during fetal development.12 These burdens are compounded by the rapidly rising prevalence of all forms of the disease. T2DM, in particular, has become one of the world’s most prevalent and chronic non-communicable diseases.9 Using mathematical models, its incidence rate was projected to rise from 16.7% in 2012 to as much as 37.7% in 2050.11 Numerically, around 425 million people were affected by the disease in 2017 and the figure was projected to rise to 629 million by 2045.13 Another 352 million people were discovered to be pre-diabetic in the same year, which may lead to T2DM if left untreated.12

The rapidly rising incidence and burden of DM worldwide is suggestive of a widespread behavioral change, noticeably among which is change in breastfeeding patterns. Breastfeeding patterns changed worldwide following the introduction of complementary foods which...
The findings of many studies indicate that the central nervous system (CNS) may help the body regulate nutrient uptake, fat deposition, energy expenditure, and physiological activities in various tissues and organs. The CNS performs these functions with the assistance of adipokines, including leptin, adiponectin, resistin, ghrelin, obestatin, apelin, irisin, and nesfatin-1 as well as some substances such as polyunsaturated fatty acids (PUFAs). These bioactive molecules have been reportedly found in breast milk, which underscores the importance of breast milk in shaping biological events that maintain energy balance in newborns through to adulthood. Thus, breast milk may help program an infant to be at a reduced risk for overweight, obesity and T2DM later in life. Each of these bioactive molecules in breast milk performs specific or related functions, which are outlined below along with the role played by breast milk’s low-calorie nutrients.

**Leptin**

Leptin is a 167-amino-acid protein encoded by the obese gene and synthesized by the adipocytes. The hormone plays a vital role in energy balance by regulating food intake (reduces appetite) and communicating the brain the amount of fat stored in various tissues and organs. Leptin improves insulin sensitivity, reducing intracellular glucose and lipid levels in skeletal muscle, liver, and pancreatic β-cells. Other functions of leptin include regulation of immune and inflammatory responses as well as in the formation of new blood vessels (angiogenesis). Leptin carries out these functions under physiological states by attaching to certain receptors embedded in the brain and peripheral tissues and organs. Outside the normal range, leptin may cause hyperphagia and decreased energy expenditure, resulting in obesity, insulin resistance, T2DM, among others. Fortunately, leptin levels in breast milk reduce with time as lactation progresses and correlates significantly with other maternal hormones.

**Adiponectin**

Adiponectin enhances glucose metabolism and insulin effectiveness in the liver as well as increases insulin sensitivity by inducing glucose uptake and fat oxidation in the skeletal muscle. Adiponectin functions right from childhood and its serum concentration is directly proportional to growth parameters, adiposity, and leptin levels. As such, adi-
ponectin may prevent the development of obesity and T2DM.\textsuperscript{21} Depletion of adiponectin levels has been linked with insulin resistance, while adiponectin supplementation by diabetics enhances insulin sensitivity.\textsuperscript{34} Aside from energy balancing, adiponectin is an anti-inflammatory molecule, which blocks reactive oxygen species, enhancing the expression of an anti-inflammatory cytokine, interleukin 10 (IL-10).\textsuperscript{32, 33} It may also inhibit NF-κB inflammatory signaling pathway and suppress tumor necrosis factor α (TNF-α) inflammatory reactions.\textsuperscript{32, 33} These show adiponectin doubles as an immune booster.

**Resistin**

Among all the adipokines in breast milk, resistin is different in that its action on glucose metabolism opposes insulin’s action on glucose.\textsuperscript{22} While insulin represses resistin synthesis, resistin induces insulin resistance—the activity from which resistin derived its name.\textsuperscript{18, 22} Resistin level in breast milk decreases as lactation progresses and correlates with circulating levels of various reproductive and metabolic hormones, which could account for its anti-diabetic property.\textsuperscript{35} A drop in the serum level of the hormone has been observed in individuals with T2DM following exercise and certain diets, improving insulin sensitivity and glucose tolerance.\textsuperscript{34} This suggests that lack of exercise and overproduction of resistin may be involved in the onset of T2DM.\textsuperscript{22} To this end, elevated plasma resistin has been shown to contribute to the impaired glucose tolerance and insulin resistance observed in T2DM through adiposity and its pro-inflammatory properties.\textsuperscript{34, 35} However, high serum resistin could be beneficial during fetal development by enhancing glucose production in the liver, preventing hypoglycemia after birth.\textsuperscript{18}

**Ghrelin**

Ghrelin is a 28-amino acid growth hormone releasing peptide, which increases body weight and adiposity by acting on the hypothalamic melanocortinergic system.\textsuperscript{37} Ghrelin is involved in fetal growth and development as it is found in cord plasma from 30 weeks into pregnancy.\textsuperscript{18} The hormone also stimulates appetite, fat deposition and rapid growth after a period of growth retardation, and its serum levels correlate with growth parameters in newborn through to infancy.\textsuperscript{18, 38} As a result of its appetite inducing property, it is referred to as hunger hormone.\textsuperscript{38} Aside ghrelin’s appetite and adiposity-inducing properties, it also helps maintain energy balance by stimulating a marked rise in plasma glucose concentrations, accompanied by a drop in insulin production.\textsuperscript{18, 38} Ghrelin may also act as a paracrine signaling molecule in the pancreas, enhancing β-cell performance.\textsuperscript{39} Loss of this function due to mutation in ghrelin precursor has been linked with insulin resistance.\textsuperscript{22} Additionally, ghrelin exerts anti-oxidant and anti-apoptotic effects on endothelial and nervous tissue, preventing diabetes-related diseases.\textsuperscript{22} Ghrelin levels have been demonstrated to be reduced in several metabolic disorders, including obesity and T2DM.\textsuperscript{40}

**Obestatin**

Obestatin is a 23-amino acid polypeptide encoded by ghrelin gene and is produced from post translational modification of preproghrelin, which is a precursor of ghrelin.\textsuperscript{41, 42} However, it works oppositely to ghrelin on food intake and plays a role in energy balance.\textsuperscript{23} Obestatin suppresses appetite, thus lessen food and water consumption as well as body weight gain and movement of foods through the digestive system.\textsuperscript{44, 45} The hormone has also been shown to increase β-cell mass, adipogenesis and lipid metabolism by up-regulating genes associated with β-cell regrowth, insulin synthesis and adipogenesis.\textsuperscript{23} A reduction in serum concentrations of obestatin as well as repression of its putative receptor named GPR39 have been reported in individuals with obesity and T2DM.\textsuperscript{46} Obestatin supplementation in diabetic rats was observed to greatly reduce plasma glucose levels and insulin resistance compared with non-treated rats in a study.\textsuperscript{47} This suggests obestatin can help to regulate blood glucose level and when combined with other materials with similar therapeutic effects, can be used to treat obesity and T2DM.\textsuperscript{47}

**Apelin**

Apelin has been shown to boost insulin sensitivity and inhibit obesity-related disorders,\textsuperscript{43} possibly through body fluid and energy homeostasis.\textsuperscript{43} The hormone is a peptide of a 12-amino acid, encoded by the APLN gene and embedded in human adipocytes.\textsuperscript{44} Apelin can exist in several active forms, including apelin-36, apelin-17, apelin-13 and apelin-12.\textsuperscript{41} Apelin controls fetal and neonatal glucose homeostasis, which can be disrupted by fetal growth retardation in malnourished mothers.\textsuperscript{45} Apelin enhances glucose and lipid metabolism as well as modulates insulin secretion.\textsuperscript{43-45} However, deficiency and high plasma concentrations of the adipokine have been observed in individuals with obesity and T2DM.\textsuperscript{44, 46, 47} This suggests that deficiency and over secretion of the hormone may be associated with the two mentioned diseases.

**Irisin**

Irisin is a myokine regulated by exercise and has been demonstrated to increase the energy expenditure by the browning of white adipose tissues.\textsuperscript{48-50} White adipocytes store energy, while brown adipocytes consume it, allowing the body to prevent fat accumulation, culminating in weight loss.\textsuperscript{45, 62} At the same time, irisin is an adipokine, secreted by the white adipose tissues,\textsuperscript{63} and elevated levels of irisin may enhance glucose homeostasis in a number of ways. These include reduction of insulin resistance, boosting of insulin receptors in skeletal muscle, enhancing hepatic glucose and lipid metabolism as
 Reduction of insulin resistance is achieved indirectly through lowering of fasting insulin.66 In a Japanese study, the serum level of irisin was positively correlated with insulin resistance in individuals with obesity.67 The scientists opined that the irisin enhancement could be a compensatory secretion in response to insulin resistance.67

**Nesfatin-1**

Nesfatin-1 is calcium and DNA binding peptide embedded in the central and peripheral nervous system as well as peripheral tissues such as digestive organs and adipose tissues.68, 69 Nesfatin-1 has many chemical messengers, which help it to reduce appetite independent of leptin, controlling body weight, energy homeostasis as well as increasing insulin secretion.69, 70 Nesfatin-1 has been demonstrated to achieve these functions by inhibiting dark-phase food intake.71 Additionally, nesfatin-1 enhances β-cell performance under hyperglycemic conditions, modulates gastrointestinal motility, improves glucose and lipid metabolism,72, 73 and influences the brain to control insulin sensitivity.74 However, high level of nesfatin-1 has been reported in newly diagnosed T2DM patients, which was reduced following treatment with anti-diabetic drugs.71 This suggests that over secretion of the hormone may induce T2DM. Impaired synthesis or release of this adipokine has also been reported among pregnant women with gestational diabetes.75

**PUFAs**

PUFAs are fatty acids consisting of two families, namely n-3 and n-6 fatty acids, each with distinct biological activities.76 The n-3 family includes alpha-linolenic acid, eicosapentaenoic acid, and docosahexaenoic acid while the n-6 family includes linolenic acid and arachidonic acid.77 PUFAs play a key role in maintaining normal cell function and its deficiency or disruption of its metabolism may cause several metabolic disorders.78 In particular, long chain polyunsaturated fatty acid can reduce fasting plasma glucose levels, insulin resistance and, thus, decrease the risk of T2DM.79, 80 Studies have shown that breast-fed infants have markedly higher concentrations of docosahexaenoic acid in their erythrocytes and brain cortex than formula-fed infants,80 indicating that breast milk contains a great amount of the fatty acid. Low concentrations of docosahexaenoic acid and other long chain polyunsaturated fatty acids in skeletal muscle membrane phospholipids have been demonstrated to aggravate insulin resistance and obesity in adults.81 Additionally, omega-3PUFAs supplementation has been shown to reduce insulin resistance and blood lipids in individuals with a high risk of T2DM.82 In a study in which dietary carbohydrate was substituted with saturated fat, there was no appreciable effect on blood glucose regulation.82 However, when carbohydrate and saturated fat were replaced with a diet rich in polyunsaturated fat, a significant glycemic control was achieved.83 This suggests that consuming more unsaturated fats instead of carbohydrates or saturated fats will improve blood glucose control.84

**Low calorie nutrients**

Lactose accounts for about 40% of calories in breast milk, while fat provides around 50%.85 This suggests that the remaining 10% is provided by other nutrients in breast milk, including proteins, vitamins and minerals. Compared to infant formula, breast milk contains significantly lower quantities of protein and energy, causing breast-fed babies to grow more slowly.86, 87 These nutritional properties of breast milk may program breast-fed babies to less dense diets later in life, resulting in moderate body weight.88 High protein intakes during infancy accelerate growth and increase fat mass, culminating in high body mass index (BMI) later in adulthood.89 Low protein consumptions may also lead to less insulin production with resultant less fat storage, preventing obesity as well as the proliferation of adipocytes.90, 91 Additionally, breastfeeding may enable babies to learn to control the amount of diet consumed, programming them to naturally regulate energy intake later in life.92

**Immunomodulating activities**

Some molecules in breast milk may strengthen the neonatal immune system through to adulthood to effectively contain several diseases, including obesity and T2DM. These molecules include antimicrobial factors, cytokines, growth factors, bioactive nutrients and maternal immune cells.93, 94

**Antimicrobial factors**

The antimicrobial factors in breast milk include glycans such as oligosaccharides, which is synthesized from lactose in the mammary gland and is often referred to as human milk oligosaccharides.95, 96 Oligosaccharides are abundant in breast milk and protect infants from microbial infection by blocking microorganisms from binding to the intestinal mucosa through the production of bacteriocins and organic acids.97 Oligosaccharides may also modulate the immune system by repressing certain pro-inflammatory genes.98 Additionally, oligosaccharides are involved in cellular communication and cell-to-cell recognition activities as well as stimulating and enriching the gut microbiota with beneficial bacteria.99 In an experiment in which intestinal epithelial cells and HeLa cells were treated with oligosaccharides, differential expressions of certain cytokines were observed.99 While the levels of some pro-inflammatory cytokine were reduced, cytokines involved in tissue repair and energy balance were enhanced. Aside oligosaccharides, breast milk naturally contains beneficial microbes, particularly *Bifidobacterium* genus and *Lactobacillus* as well as *Streptococcus* and *Staphylococcus*, all which may
populate neonate gut, strengthening it against harmful microbes. The breast milk microbes may also stimulate anti-inflammatory activities through the production of certain cytokines, reducing several inflammatory diseases, including T2DM later in life.

**Cytokines**

Some of the cytokines in breast milk that are important to obesity and T2DM pathogenesis and prevention include interleukin 1 (IL-1), interleukin 6 (IL-6), and interleukin 10 (IL-10). IL-1 is a group of pro-inflammatory cytokines and high concentrations of it have been linked with obesity, disruption of pro-insulin synthesis, and β-cell apoptosis. However, at moderate concentrations, IL-1 stimulates pro-insulin synthesis, thereby decreasing circulating blood sugar levels. Moreover, the IL-1 family has an anti-inflammatory member, named interleukin 37 (IL-37), and has been demonstrated to prevent obesity-induced inflammation and insulin resistance.

Although interleukin-6 (IL-6) is a known pro-inflammatory cytokine, it also takes part in anti-inflammatory activities involving neuronal function and development. IL-6 is secreted by several tissues, particularly adipose tissue and, at high concentrations, may induce insulin resistance, obesity and T2DM. However, the presence of IL-6 is normal and, acute administration of it, has been shown to improve insulin resistance and mediate glucose uptake. Breast milk IL-6 concentration has been demonstrated to have negative associations with infant growth parameters and adiposity. Moreover, IL-6 may be anti-inflammatory by enhancing the production of other anti-inflammatory cytokines such as IL-1ra and IL-10 while suppressing the synthesis of the pro-inflammatory cytokine TNF-α.

IL-10 is an anti-inflammatory cytokine that inhibits pro-inflammatory cytokines while up-regulating the anti-inflammatory ones. IL-10 is thought to prevent aging-related inflammation, insulin resistance in skeletal muscle, and T2DM. According to Hong et al. (2009), IL-10 enhances insulin sensitivity, prevents infiltration of skeletal muscle by obesity-associated macrophages, and suppresses pro-inflammatory cytokines along with their inhibitory actions on insulin signaling and glucose metabolism. IL-10 is so important, its under-expression has been shown to play a key role in severe inflammatory diseases such as T2DM.

The most abundant cytokine in breast milk is the transforming growth factor beta (TGF-β), which belongs to the transforming growth factor superfamily. Members of this cytokine family include TGF-β1 to β4 as well as activins, bone morphogenetic proteins, growth and differentiation factors, among others. Several studies have shown that TGF-β family ligands can regulate glucose homeostasis by enhancing β-cell function and, in adults, can boost β-cell mass or accumulation from progenitors. These ligands can also be influenced by their soluble antagonists to maintain glucose homeostasis.

**Growth factors**

Epidermal growth factor (EGF) and insulin-like growth factor (IGF) are the two major breast milk growth factors with anti-diabetic properties. EGF is synthesized in the pancreas and has been shown to enhance the proliferation of diverse cells. Specifically, some members of the EGF family are being suspected to be involved in the development of the pancreas. In an experiment, EGF increased insulin secretion in mouse pancreatic islets and in a pancreatic β-cell line within a short duration, while diabetic animals were shown to be deficient of EGF. In another study, EGF increased plasma insulin levels and lowered blood glucose levels in healthy and diabetic mice. Additionally, epidermal growth factor receptor is massively expressed in the pancreas of developing human fetus, and mice deficient of the receptor has been demonstrated to show malfunctioned pancreatic islets.

IGF is a superfamily comprising of IGF-I, IGF-II, insulin-like growth factor binding proteins (IGFBPs) and insulin-like growth factor specific proteases (IGFS). Nearly half of the IGF-I amino acid sequence resembles that of insulin and produces almost the same blood glucose lowering effect. However, experimental findings have shown that deficiency and overproduction of IGF-I can disrupt glucose metabolism and increase T2DM risk. Normal levels of IGF-binding protein-2 (IGFBP-2) promotes glucose metabolism and inhibits the pathogenesis of obesity and insulin resistance, while its deficiency has been implicated in some metabolic disorders.

**Bioactive nutrients (carbohydrates, fatty acids, minerals, vitamins and proteins)**

Aside from nutritional provision, some nutrients are bioactive and may serve some other functions. Lactose and, oligosaccharides discussed earlier, are the main carbohydrates in breast milk and lactose has been shown to deliver non-insulinogenic carbohydrate to infants. This unique form of carbohydrate gradually metabolizes to glucose in the liver as well as enhancing fatty acid oxidation, thus helps to maintain glucose and insulin balance. Moreover, lactose inhibits the proliferation of harmful gut bacteria, while stimulating the growth of beneficial ones, resulting in improved calcium, phosphorus and magnesium absorption. Long chain polysaturated fatty acids, discussed earlier, protect β-cells from the cytotoxic effects of alloxan. Long-chain polysaturated fatty acids also inhibit inflammatory activities of TNF-α, which may explain the bene-
Breast milk contains several bioactive proteins whose bioactivities include enzyme activities, boosting of nutrient absorption, growth stimulation, strengthening of the immune system and antimicrobial activities. Some of the bioactive proteins in breast milk include lactoferrin, lysozyme, secretory immunoglobulin A (sIgA), haptocorrin, bile salt stimulated lipase, β- and κ-casein, among others. Majority of these bioactive factors are abundant in breast milk and stimulate immunomodulatory, anti-inflammatory, and antimicrobial activities in neonates. The mentioned bioactive factors employ several mechanisms in their antimicrobial activities, including proliferation of beneficial microorganisms and phagocytosis or inhibition of proliferation of harmful microorganisms. The bioactive factors may also devise some other mechanisms that prevent attachment or invasion of harmful microorganisms. For example, lactoferrin can inhibit pathogens by binding to iron and making it inaccessible to pathogens which require iron to grow, thus preventing infection as well as inflammatory disorders.

**Maternal immune cells**

Several studies have shown that breast milk contains abundant maternal immune cells, which modulate neonatal immunity through to adulthood, preventing diseases such as obesity and T2DM. These maternal cells include immune cells (leukocytes), stem cells, and mammary cells released from breast tissue. The leukocytes are far more abundant in colostrum and include neutrophils, macrophages and lymphocytes; each with the distinct role, but work synergistically to fight infections. Newborns consume nearly 100 million maternal cells daily, mostly leukocytes. Leukocytes inhibit harmful microbes in the breast while at the same time populate baby’s gut microbiota and strengthen its defense mechanism. Most of the leukocytes in breast milk are neutrophils, which decline from six weeks after birth, protecting breast and the infant from infections. The second most abundant immune cell in breast milk is the macrophage, accounting for about 40% of the leukocytes in colostrum and is phagocytic like the neutrophils. In the gut, macrophages synthesize and up-regulate lysozyme as well as stimulate lymphocytes against pathogens. The third mentioned immune cell, lymphocyte, produces several immune-boosting chemicals such as gamma-interferon, migration inhibition factor and monocyte chemotactic factor.

Another immune cell named innate lymphoid cell has also been isolated in breast milk. It may occupy the gut of newborns temporarily, protecting the baby from pathogens and inflammation as well as training its immature immune system and modulating its gut microbiota. Innate lymphoid cell is unique in that it does not directly fight infections. Instead, it senses inflamed cells in infected tissues and through cellular signaling communicate and coordinate other immune cells to swing into action.

**Formulation of Infant Formula using Breast milk as a Baseline**

The busy schedules of some nursing moms and some health issues have frequently denied some babies access to breastfeeding, and has necessitated the manufacturing of several infant formulas. However, for babies of such moms to enjoy the same benefits as naturally breast-fed infants, infant formula must be formulated based on the bioactive substances and nutrients in breast milk. Key messages from this review, which may serve as guides for formulating infant formula are summarized below:

1. An infant formula should contain low calorie and nutritional protein.

2. The formula should contain adipokines such as leptin, adiponectin, resistin, ghrelin, obestatin, apelin, irisin, and nesfatin-1 as well as PUFAs. However, leptin, resistin, apelin, irisin, and nesfatin-1 should not exceed the normal physiological range.

3. Antimicrobial factors such as oligosaccharides as well as some naturally beneficial bacteria such as *Bifidobacterium genus* and *Lactobacillus*, among others, should be included in the formula.

4. The formula should also contain moderate quantities of some pro-inflammatory cytokines, including IL-1β and IL-6 and abundant anti-inflammatory cytokines such as IL-10, IL-37, and TGF-β.

5. Some growth factors, particularly EGF and IGF (e.g. IGF-1 and IGFBPs) should be added however, IGF-1 should be kept at a physiological range.

6. The formula must also contain abundant bioactive nutrients such as lactose as well as some major vitamins and minerals. Some bioactive proteins such as lactoferrin, lysozyme, sIgA, haptocorrin, bile salt stimulated lipase, β- and κ-casein, among others, should also be included.
Conclusion

From the literature reviewed, it is clear that breast milk contains abundant bioactive molecules and nutrients. These substances protect newborns from infections and inflammation as well as train the immune system of infants, preventing short and long-term diseases such as obesity and T2DM, among others. Nursing mothers are, therefore, advised to breastfeed their babies adequately, at least six months, before introducing complementary foods. Healthcare providers, particularly nutritionists, are also advised to formulate infant formula using breast milk as standard, to satisfy the needs of babies who may not have access to breastfeeding. Moreover, breast milk is dynamic and its quality and quantity depend on several internal and external factors. As such, for babies to derive maximum benefits from breastfeeding, nursing mothers should eat balanced diets, keep personal hygiene and be emotionally and psychologically stable. Breast milk is also deficient of some vitamins, particularly vitamins D and K, so exclusive breastfeeding should be done with vitamin supplementation with the advice of a qualified personnel.

Conflict of interest

The authors have no conflicting interest to declare.

References


70. Ayada C, Toru Ü, Korkut Y. Nesfatin-1 and its effects on different systems. Hippokratia 2015; 19: 4-10.
75. Mierzynska R, Poniedziałek-Czajkowska E, Dłuski D, Patro-Mażyś J, Kimber-Trojan Z, Majsterek M, Leszczyńska-Gorzelał B. Nesfatin-1 and vaspin as potential novel biomarkers for the predic-
94. Fain JN, Gerald L. Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. Vitam Horm. 2006; 74: 443-77.
100. Bastard JP, Maachi M, van Nhlie JT, Jardel C, Bruckert E, Grimaldi A, Robert JJ, Capeau J. Hainque B. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab. 2002; 87: 2084-89.
103. Petersen AMW, Pedersen BK. The anti-inflammatory...

104. Barry JC, Shakibakho S, Durrer C, Simtchouk S, Jawanda KK, Cheung SF, Mui AL, Little JP. Hypo-

DA, Hu X, Loubato MM. IL-10 prevents aging-
associated inflammation and insulin resistance in 

106. Hong EG, Ko HJ, Cho YR, Kim HJ, Ma Z, Tim YY, 
Friedline RH, Kurt-Jones E, Finberg R, Fischer 
MA, Granger EL. Interleukin-10 prevents diet-
induced insulin resistance by attenuating macrophage and cytokine response in skeletal 

107. Dawod B, Marshall JS. Cytokines and soluble 
receptors in breast milk as enhancers of oral 
tolerance development. Front Immunol. 2019; 10:
16.

108. Morikawa M, Derynck R, Miyazono K. TGF-β 
and the TGF-β family: Context-dependent roles in 
cell and tissue physiology. Cold Spring Harb 

109. Brown ML, Schnyder AL. Emerging roles for the 
TGFβ family in β-cell homeostasis. Trends Endo-

NA, Schnyder AL. Differential synthesis and 
action of TGFβ superfamily ligands in mouse and 

111. Lu M, Jiang J, Wua K, Li D. Epidermal growth 
factor and transforming growth factor-α in human 
milk of different lactation stages and different 
regions and their relationship with maternal diet. 
Food Funct. 2018; 9: 1199-204.

112. Lee HY, Yea K, Kim J, Lee BD, Chae YC, Kim HS, 
Lee DW, Kim SH, Cho JH, Jin CJ, Koh 
DS. Epidermal growth factor increases insulin 
secretion and lowers blood glucose in diabetic 

113. Schlessinger J, Ligand-induced, receptor-mediated 
dimerization and activation of EGF recep-

growth factor-induced proliferation of chicken 
primordial germ cells: Involvement of calcium/ 
protein kinase C and NFKB1. Biol Reprod. 2009; 
80: 528-36.

115. Miettinen P, Ormio P, Hakonen E, Banerjee M, 
Otonkoski T. EGF receptor in pancreatic β-cell 
mass regulation. Biochem Soc Trans. 2008; 36: 280- 
85.

116. Bayes-Genis A, Conover CA, Schwartz RS. The 
125-30.

117. Friedrich N, Thuesen B, Jørgensen T, Juul A, 
Spießhagen C, Wallaschoksi H, Linneberg A. The 
association between IGF-I and insulin resistance. 

118. Aguirre GA, De Ita JR, de la Garza RG, Castilla-
Cortazar I. Insulin-like growth factor-1 deficiency 

119. Wheatcroft SB, Kearney MT, Shah AM, Ezzat VA, 
Miell JR, Modo M, Williams SC, Cavethorn WP, 
Medina-Gomez G, Vidal-Puig A, Sethi JK. IGF-
binding protein-2 protects against the develop-
ment of obesity and insulin resistance. Diabetes 

120. Assesa B, Mahmoud AM, Pfeiffer AF, Birkenfeld 
AL, Spranger J, Arafat AM. Insulin-like growth 
factor (IGF) binding protein-2, independently of 
IGF-1, induces GLUT-4 translocation and glucose 
uptake in 3T3-L1 adipocytes. Oxid Med Cell 

121. Heal AH, Kausal K, Siddals KW, Rudenski AS, 
Anderson SG, Gibson JM. Insulin-like growth 
factor binding protein-2 (IGFBP-2) is a marker for 
the metabolic syndrome. Exp Clin Endocrinol 
Diabetes. 2006; 114: 371-76.

122. Palmeira P, Carneiro-Sampaio M. Immunology of 

123. Martin CR, Ling P, Blackburn GL. Review of 
infant feeding: Key features of breast milk and 

124. Lønnertdal B. Bioactive proteins in breast milk. J 
Paediatr Child Health. 2013; 49 (S1).

125. Siqueiros-Cendón T, Arévalo-Gallegos S, Iglesias-
Figueroa BF, García-Montoya IA, Salazar-Marti-
nez J, Rascón-Cruz Q. Immunomodulatory effects 
of lactoferrin. Acta Pharmacol Sin. 2014; 35: 557-
66.

126. Cacho NT, Lawrence RM. Innate immunity and 

127. Bahan B, Malik A, Bhata J, Yu JC. Presence and 
profile of innate lymphoid cells in human breast 

128. Cabinian A, Sinsimer D, Tang M, Zumba O, 
Mehta H, Toma A, Sant'Angelo D, Laouar Y, 
Laouar A. Transfer of maternal immune cells by 
breastfeeding: Maternal cytokotoxic T lymphocytes 
present in breast milk localize in the Peyer's 
patches of the nursed infant. PLoS One. 2016; 11: 
e0156762.

Available online from http://www.breastfeeding-
online.com/HowBreastmilkProtectsNewborns.pdf